Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPOLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPOLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPOLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPOLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPOLORE MOREGeneral Control Protein GCN4, is a transcription factor for over 30 genes necessary for amino acid or purine biosynthesis in the case of amino acid or purine starvation. As a transcription factor located in the nucleus, GCN4 regulates many genes connected to purine biosynthesis, autophagy, multiple stress responses, glycogen homeostasis, and organelle biosynthesis. A specific antibody conjugated to GCN4 peptide can be used to redirect the activity of the CAR-T cells to antigen expressing cancer cells.
Associated Disease | CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | |
| CAR-LC281 | Anti-GCN4 (52SR4) h(41BB-CD3ζ, GCN4 (52SR4)) Conditional CAR, pCDCAR1 | 52SR4 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
